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 Abstract 
 Background: Pulmonary metastases occur in 10–20% of patients with colorectal cancer and 
significantly influence long-term survival. In this study, the immunological architecture of 
colorectal lung in comparison to liver metastases and its impact on patient survival were ex-
amined.  Methods: Specimens of patients with colorectal lung and liver metastases were 
stained for HE, CD4, CD8, CD20, CD68 and CD45RO. Besides histomorphological evaluation, 
immunohistochemical stainings were analyzed for the respective cell numbers separately for 
tumor area, infiltrative margin and distant lung or liver stroma. These findings were corre-
lated with clinical data and patient outcome.  Results: In colorectal lung (n = 69) in comparison 
to liver (n = 222) metastases, the immunological focus is located in the tumor region. A high 
CD4 + cell infiltration of this area is associated with prolonged survival of patients after resec-
tion of colorectal lung metastases [103 ± 33 (high) vs. 37 ± 6 months (low); p = 0.0246]. Pa-
tients who were treated with preoperative chemotherapy did not show differences in immune 
infiltrates compared to chemotherapy-naïve patients.  Conclusion: Colorectal lung and liver 
metastases showed a distinct immunological architecture. A dense cell infiltration of colorec-
tal lung metastases by CD4 + cells was related to prolonged patient survival. Preoperative che-
motherapy did not influence cellular immune infiltrates.  © 2016 S. Karger AG, Basel 
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 Introduction 
 Therapy decisions in patients with primary colorectal carcinomas are currently made 
according to guidelines based on the UICC/AJCC TNM system that stages these tumors by the 
extent of wall infiltration of resected tissue and the presence of metastases  [1] . To explain 
considerable outcome variations of patients staged in the same histological category, the 
immunological tumor microenvironment and its effect on patient outcome have been exten-
sively investigated  [2–6] . These studies of primary colorectal carcinomas have demonstrated 
beneficial survival effects of tumor infiltration by CD4 + Th1, CD8 + cytotoxic and CD45RO + 
memory T cells, whereas Th17 cell infiltration is associated with poor patient survival  [7–9] . 
Based on these new results, immune scores have been developed to prognosticate patient 
survival, which have been proposed as a new component for classification of primary co-
lorectal carcinoma  [10] . In addition to these scores, our group investigated colorectal liver 
metastases, which occur in 40–50% of patients with colorectal cancer and determine long-
term survival, in order to elucidate their immune architecture  [3] . In this study, we demon-
strated that peritumoral infiltration of CD45RO + cells and a fibrotic capsule containing the 
liver metastases were independent prognosticators for prolonged survival of patients with 
colorectal liver metastases  [3] . Based on these two factors, we developed a cellular immune 
score to stratify patients according to prognosis, which can be included in the proposed 
immune scoring concepts  [3] . Not only liver metastases, but also pulmonary metastases, 
which occur in 10–20% of patients, limit the prognosis of patients with colorectal carcinoma 
 [11,  12] . Despite the fact that pulmonary metastases are the most frequent extraabdominal 
site of colorectal metastasis, studies that investigated their immune infiltrate are lacking so 
far  [13] . To address this problem, this study elucidated the immunological tumor microen-
vironment of pulmonary metastases of colorectal carcinoma under the hypothesis that a 
distinct immune architecture is associated with prolonged patient survival. We further 
aimed to elaborate differences between immune infiltrates of colorectal liver and lung 
metastases. 
 Methods 
 Patient Selection and Data Collection 
 This study was performed at the University Medical Center of Regensburg, Germany, and was approved 
by the local ethics committee (No. 12-101-0009). Patients with colorectal lung metastases (confirmed by 
histology) who underwent pulmonary surgery at the University Medical Center of Regensburg or at the 
teaching hospital Barmherzige Brüder Regensburg between 2004 and 2010 were identified using the hospital 
computer database. For comparison of immune infiltrates, patients with colorectal liver metastases (confirmed 
by histology) who underwent liver surgery at the University Medical Center of Regensburg between 2004 and 
2010 were identified using the hospital computer database. Only patients receiving primary lung resection 
with curative intent were included (achieved in 97.1% of pulmonary resections). In case of multiple lung 
metastases, the largest was used for analysis. General patient information, TNM classification of primary 
tumors and histological data on colorectal lung and liver metastases were obtained from the routine pathology 
report. If patients had received chemotherapy within 3 months prior to lung resection, this was assessed as 
‘preoperative chemotherapy’. This included patients that received chemotherapy for pulmonary metastases, 
for synchronous pulmonary and liver metastases and for the primary tumor. The period of 3 months was 
chosen to investigate chemotherapeutical effects on immune infiltrates, which would be expected to be much 
smaller in case of longer time periods accounted for ‘preoperative’ chemotherapy. Survival data were collected 
using the database of the Tumorzentrum Regensburg (regional tumor center of East Bavaria), Germany. 
 Histological Analysis 
 Tissue cross sections were stained for CD4, CD8, CD45RO, CD20 and CD68 (described in detail in online 
suppl. materials; for all online suppl. material, see www.karger.com/doi/10.1159/000447555). Digital 
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images of lung and liver metastases were obtained at ×20 magnification on light microscopy (Carl Zeiss 
MicroImaging GmbH, Jena, Germany).
 The numbers of CD4 + , CD8 + , CD45RO + , CD20 + and CD68 + cells were manually counted in 3 randomly 
selected areas (×20 magnification) using ImageJ 1.45s software (Wayne Rasband, National Institutes of 
Health, USA; example in online suppl. materials) and the mean was taken separately for tumor region (Tu), 
infiltrative margin (Im) and distant stroma (Sd). Im was defined as the area within one field of view (×20) 
next to the tumor, and Sd was defined as outmost area of the specimen in a region that was tumor free.
 For survival analyses, patients were divided into two groups depending on the numbers of CD4 + , CD20 + , 
CD45RO + , CD68 + and CD8 + cells in the different areas. Cell numbers larger than the respective mean were 
defined as ‘high’, smaller as ‘low’.
 Statistical Analysis 
 Kaplan-Meier graphs were calculated for overall survival analyses. Group comparisons were made 
using the log-rank test. Patient data are presented as median with interquartile range (IQR) or as number 
with percentages. To evaluate correlations, Pearson’s correlation, and for continuous variables the Mann-
Whitney test was used. The level of significance was set at p < 0.05. All histological evaluations were performed 
independently in a blinded fashion by 2 examiners (S.M.B., U.H.). In case of divergent evaluation, consensus 
was achieved reevaluating the cross sections together. To explore reproducibility after some time, random 
samples were drawn and reevaluated. In all histological evaluations, the concordance rate between the 
observers and the reproducibility of the results was >95%.
 Results 
 Patient Characteristics 
 A total of 69 patients (24 female, 35%; 45 male, 65%) with colorectal lung metastases with 
a median age of 64 years (IQR 57–71) were enrolled. For detailed information on patient char-
acteristics, see  table 1 . Overall median survival time was 33 months (IQR 17–56) after lung 
surgery with a 3-year survival rate of 44%. The immune infiltrates of these patients with lung 
metastases were compared with a collective of 222 patients (83 female, 41%; 118 male, 59%) 
with a median age of 62 years (IQR 53–68) after resection of colorectal liver metastases  [3] .
 Table 1. Clinical characteristics of patients with colorectal lung metastases
Yes No 
Male 45 (65.2) 24 (34.8)
Nicotine abuse 13 (18.8) 56 (81.2)
Pulmonary disease 9 (13.0) 60 (87.0)
Synchronous lung metastases 6 (8.7) 63 (91.3)
Singular lung metastases 43 (62.3) 26 (37.7)
R0 resection of lung metastases 67 (97.1) 2 (2.9)
Lymphadenectomy 48 (69.6) 21 (30.4)
Pulmonary lymph nodes positive (out of lymphadenect omy)a 8 (16.7) 40 (83.3)
Neoadjuvant chemotherapy prior to resection of lung metastases 12 (17.4) 57 (82.6)
Adjuvant chemotherapy after resection of lung metastases 18 (26.1) 51 (73.9)
Primary tumor colon/rectum 23 (33.3) 46 (66.7)
Primary tumor lymph node metastases 36 (52.2) 33 (47.8)
Synchronous liver metastases 3 (4.3) 66 (95.7)
Primary tumor G2/G3b 48 (80.0) 12 (20.0)
Primary tumor R0b 54 (91.5) 5 (8.5)
 Data are presented as n (%). a Only performed in 48 patients. b Some histology reports of primary tumors 
incomplete.
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 Cellular Immune Infiltration Pattern Is Different in Colorectal Lung Compared to Liver 
Metastases 
 Cellular immune infiltration was analyzed separately for Tu, Im and Sd in the comparison 
between colorectal lung and liver metastases. In the Tu, the infiltration by CD4 + cells was 
comparable between the liver and lung (liver 40 ± 3 vs. lung 42 ± 15 cells/HPF; p = 0.8408), 
whereas in the Im (liver 261 ± 11 vs. lung 54 ± 6 cells/HPF; p < 0.0001) and also in the Sd 
(liver 66 ± 4 vs. lung 13 ± 2 cells/HPF; p < 0.0001), liver samples showed significantly higher 
CD4 + cell numbers when compared to lung tissue ( fig. 1 a). Regarding CD8 + cells, the Tu 
showed a similar cell infiltration in the liver and lung samples (liver 28 ± 3 vs. lung 26 ± 4 
cells/HPF; p = 0.6856), with cell numbers being significantly higher in liver tissue when 
compared to lung tissue in the Im (liver 149 ± 7 vs. lung 46 ± 5 cells/HPF; p < 0.0001) and in 
a b
c
 Fig. 1. Cellular infiltration of colorectal lung in comparison to colorectal liver metastases.  a Infiltration by 
CD4 + cells in the Tu of the liver and lung was comparable (liver 40 ± 3 vs. lung 42 ± 15 cells/HPF; p = 0.8408), 
whereas in the Im (liver 261 ± 11 vs. lung 54 ± 6 cells/HPF; p < 0.0001) and Sd (liver 66 ± 4 vs. lung 13 ± 2 
cells/HPF; p < 0.0001) regions, liver samples showed significantly higher CD4 + cell numbers.  b Infiltration 
by CD8 + cells in the Tu was similar in the liver and lung samples (liver 28 ± 3 vs. lung 26 ± 4 cells/HPF; p = 
0.6856), with significantly higher cell numbers in the liver compared to the lung tissue in the Im (liver 149 ± 
7 vs. lung 46 ± 5 cells/HPF; p < 0.0001) and Sd (liver 61 ± 4 vs. lung 11 ± 1 cells/HPF; p < 0.0001) regions.
 c Infiltration by CD45RO + cells in the Tu was comparable in the liver and lung samples (liver 62 ± 5 vs. lung 
99 ± 43 cells/HPF; p = 0.1561), whereas the cell numbers of liver samples were significantly higher in the Im 
(liver 272 ± 11 vs. lung 107 ± 17 cells/HPF; p < 0.0001) and Sd (liver 78 ± 6 vs. lung 30 ± 3 cells/HPF; p < 
0.0001) regions.  * p < 0.05. 
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the Sd (liver 61 ± 4 vs. lung 11 ± 1 cells/HPF; p < 0.0001;  fig. 1 b). Also in the analysis of 
CD45RO + cells, no significant infiltration difference was noted in the Tu (liver 62 ± 5 vs. lung 
99 ± 43 cells/HPF; p = 0.1561), whereas the cell numbers of liver samples were significantly 
higher in the Im (liver 272 ± 11 vs. lung 107 ± 17 cells/HPF; p < 0.0001) and in the Sd (liver 
78 ± 6 vs. lung 30 ± 3 cells/HPF; p < 0.0001;  fig. 1 c). CD20 + (Tu 14 ± 8; Im 14 ± 3; Sd 1 ± 1 
cells/HPF; p = 0.1045) and CD68 + (Tu 8 ± 3; Im 32 ± 3; Sd 26 ± 2 cells/HPF; p < 0.0001) cells 
were only analyzed in lung samples without statistically significant differences for CD20 + 
cells and significant lower numbers of CD68 + cells in the Tu compared to the Im and Sd (online 
suppl. fig. 1A, B). Additionally, it was noted that in lung metastases, the infiltration of CD4 + , 
CD8 + , CD45RO + and CD20 + cells was significantly less in the distant lung tissue when compared 
to the Tu and Im. To test if differences in the immune infiltrates of multiple metastases in one 
single patient might have relevant implications on the results of this study, we analyzed CD4 + 
cell numbers in 2 different lung metastases. In this comparison of the respective areas of the 
two metastases, we did not detect any significant differences (online suppl. fig. 4).
 Cellular Infiltration Pattern of Colorectal Lung Metastases Influences Patient Survival 
 For survival analysis, the patients were divided into a group with a high infiltration and 
a group with a low infiltration by the respective cells. Cell numbers larger than the respective 
mean were defined as ‘high’, smaller as ‘low’. Significantly increased patient survival was 
noted in patients with high CD4 + [103 ± 33 vs. 37 ± 6 months; hazard ratio 2.91 (95% CI 1.17–
4.98); p = 0.0246;  fig. 2 b] cell numbers in the Tu region compared to patients with a low infil-
tration by these cells. In contrast, no statistically significant survival differences based on 
CD4 + cell infiltration in the Im (p = 0.3903;  fig. 2 c) and in the Sd area were detected (p = 
0.6291;  fig. 2 d). Further, the survival of patients with high CD8 + (Tu p = 0.4359; Im p = 0.8148; 
Sd p = 0.5402;  fig. 3 ), CD45RO + (Tu p = 0.5368; Im p = 0.3343; Sd p = 0.8156;  fig. 4 ), CD20 + 
(Tu p = 0.6110; Im p = 0.6475; Sd p = 0.8420; online suppl. fig. 2) and CD68 + cell numbers (Tu 
P = 0.8298; Im p = 0.2302; Sd p = 0.2591; online suppl. fig. 3) was not different from that of 
patients with a low infiltration by the respective cells in the 3 different sample regions 
analyzed.
 Preoperative Chemotherapy Does Not Influence Cellular Immune Infiltrates of Colorectal 
Lung Metastases 
 A statistical analysis that compared patients receiving or not receiving preoperative 
chemotherapy revealed that the respective patient groups generally were comparable with 
regard to clinical factors. Further, the administration of preoperative chemotherapy did not 
influence immune cell infiltration of colorectal lung metastases. More specifically, the numbers 
of CD4 + , CD20 + , CD45RO + , CD68 + and CD8 + cells in the Tu, but also in the Im and in the distant 
lung areas were not statistically different between patients that received preoperative chemo-
therapy and chemotherapy-naïve patients ( table 2 ). 
 Discussion 
 In this study, a comparative analysis of colorectal lung and liver metastases detected 
relevant differences in immune cell infiltrates. More specifically, colorectal liver metastases 
showed significantly higher numbers of infiltrating cells especially in the Im which demon-
strates that in the liver the main immunological interference between host and tumor takes 
place in this area. This is supported by a previous study that discovered significant differ-
ences in patient survival in case of a dense infiltration by CD4 + , CD45RO + and CD8 + cells in the 
Im  [3] . In contrast to this infiltration pattern typical for the liver, the examined lung metas-
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tases showed a homogenous cell infiltration of the Tu and Im with significantly decreased cell 
accumulation in the distant lung tissue. This depicts that the immunological site of action in 
colorectal lung metastases is located in the Tu and in its Im. However, survival is associated 
with cell infiltration in the tumor. 
 To prove that this pulmonary-specific cellular immune architecture has implications for 
survival of patients after resection of colorectal lung metastases, a survival analysis was 
performed comparing patients with a ‘high’ and ‘low’ immune cell infiltration in the respective 
areas. Indeed, patients with a ‘high’ infiltration by CD4 + cells within the Tu survived signifi-
cantly longer when compared to patients with a low CD4+ cell infiltration. This is in accor-
dance with previous studies that found CD4 + Th1 cells infiltrating the primary colorectal 
carcinoma to be beneficial for long-term patient survival and that this fact can be used for risk 
stratification  [8, 9, 14, 15]. These survival differences with regard to CD4 + cell infiltration in 
the Tu were not detectable in the Im and in the lung periphery, which underlines the immu-
a
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 Fig. 2. Dense infiltration of CD4 + cells in the tumor is associated with increased patient survival.  a Represen-
tative immunohistochemical stainings for CD4 + cells (brown; color refers to the online version only) sepa-
rately for the Tu, Im and Sd.  b Increased survival was noted in patients with high CD4 + cell numbers in the 
Tu compared to patients with a low infiltration by CD4 + cells [hazard ratio 2.91 (95% CI 1.17–4.98); p = 
0.0246].  c Survival of patients with high CD4 + cell numbers in the Im was not different to that of patients with 
a low infiltration by these cells (p = 0.3903).  d No statistical difference in survival was detected between pa-
tients with low and high CD4 + cell numbers in the Sd area (p = 0.6291).  * p < 0.05. 
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nological importance of the Tu specifically in lung metastases. This finding is supported by a 
study that compared colorectal lung metastases with their primary tumor and renal cell 
carcinoma lung metastases. In this study, a ‘high’ cell infiltration of the Tu by CD8 + , DC-LAMP + 
mature dendritic cells and NKp46 + NK cells was associated with a better patient survival  [16] . 
In our study, these results could not be confirmed for CD8 + cells. However, the survival differ-
ences with regard to CD4 + cell infiltration in the Tu add an essential fact to the picture of 
immune cell architecture of colorectal lung metastases. Further, Remark et al. [16] found that 
the immune infiltrates of primary colorectal carcinomas and their lung metastases are simi-
lar, whereas colorectal liver metastases in our study show differences in the immunological 
architecture when compared to their lung metastases not only with regard to the region but 
also with regard to the type of cells that are responsible for survival differences.
 Another important finding of this study is that preoperative chemotherapy of patients 
that are resected for colorectal lung metastases does not influence the immune infiltrate. This 
a
dcb
 Fig. 3. Dense infiltration of CD8 + cells does not influence patient survival.  a Representative immunohisto-
chemical stainings for CD8 + cells (brown; color refers to the online version only) separately for the Tu, Im 
and Sd.  b Survival did not differ in patients with high CD8 + cell numbers in the Tu compared to patients with 
a low infiltration by CD8 + cells (p = 0.4359).  c Survival of patients with high CD8 + cell numbers in the Im was 
not different to that of patients with a low infiltration by these cells (p = 0.8148).  d No statistical difference 
in survival was detected between patients with low and high CD8 + cell numbers in the Sd area (p = 0.5402). 
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is highly relevant, since interference of chemotherapy with a beneficial immune infiltration 
phenotype could potentially lead to even worsened patient outcome  [17] . This negative effect 
has been described after radiochemotherapy of esophageal cancer  [18] . However, there are 
no reports about the influence of chemotherapy on the immune infiltrates of colorectal lung 
metastases so far. Generally, there are no prospective randomized controlled trials investi-
gating the role of chemotherapy after resection of colorectal lung metastases  [13] . A meta-
analysis by Gonzalez et al. [19] including 25 studies and a total of 2,925 patients did not detect 
chemotherapy to be associated with prolonged survival after resection of colorectal lung 
metastases. Further, there are reports that adjuvant chemotherapy is marginally beneficial 
after combined resection of colorectal liver and lung metastases; however, it remains unclear 
if this can be extrapolated to the situation after resection of colorectal lung metastases alone 
 [20, 21] . 
a
dcb
 Fig. 4. Dense infiltration of CD45RO + cells does not influence patient survival.  a Representative immunohis-
tochemical stainings for CD45RO + cells (brown; color refers to the online version only) separately for the Tu, 
Im and Sd.  b Survival did not differ in patients with high CD45RO + cell numbers in the Tu compared to pa-
tients with a low infiltration by CD45RO + cells (p = 0.5368). c Survival of patients with high CD45RO + cell 
numbers in the Im was not different to that of patients with a low infiltration by these cells (p = 0.3343).
 d No statistical difference in survival was detected between patients with low and high CD45RO + cell num-
bers in the Sd area (p = 0.8156). 
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Criteria  Preoperative chemotherapy
y es 
(n = 12)
no 
(n = 57)
p 
value
Male Yes 6  (8.7) 18 (26.1) 0.223
No 6 (8.7) 39 (56.5)
Nicotine abuse Yes 0 13 (18.8) 0.066
No 12 (17.4) 44 (63.8)
Pulmonary disease Yes 0 9 (13.0) 0.014*
No 12 (17.4) 48 (69.6)
R0 resection of lung 
metastases 
Yes 11 (15.9) 56 (81.6) 0.217
No 1 (1.4) 1 (1.4)
Lymphadenectomy Yes 7 (10.1) 41 (59.4) 0.352
No 5 (7.2) 16 (23.2)
Pulmonary lymph nodes 
positive (out of 
lymphadenectomy)a
Yes 1 (2.1) 7 (14.6) 0.855
No 6 (12.5) 34 (70.8)
Primary tumor colon/
rectum
Colon 7 (10.1) 16 (23.2) 0.124
Rectum 5 (7.2) 41 (59.4)
Primary tumor lymph node 
metastases
Yes 5 (7.2) 31 (44.9) 0.423
No 7 (10.1) 26 (37.7)
Primary tumor R0b Yes 9 (13.0) 45 (65.2) 0.338
No 1 (1.4) 4 (5.8)
 CD4 Sdc High 5 (7.4) 19 (27.9) 0.611
Low 7 (10.3) 37 (54.4)
CD4 Im High 4 (5.8) 20 (29.0) 0.908
Low 8 (11.6) 37 (53.6)
CD4 Tu High 3 (4.3) 8 (11.6) 0.346
Low 9 (13.0) 49 (71.0)
 CD45RO Sdc High 7 (10.3) 18 (26.5) 0.088
Low 5 (7.4) 38 (55.9)
CD45RO Im High 4 (5.8) 15 (21.7) 0.621
Low 8 (11.6) 42 (60.9)
CD45RO Tuc High 2 (2.9) 9 (13.2) 0.959
Low 10 (14.7) 47 (69.1)
CD20 Sdc High 2 (2.9) 11 (16.2) 0.812
Low 10 (14.7) 45 (66.2)
CD20 Imc High 0 12 (17.6) 0.077
Low 12 (17.6) 44 (64.7)
CD20 Tuc High 0 5 (7.4) 0.282
Low 12 (17.6) 51 (75.0)
 CD8 Sdc High 5 (7.4) 24 (35.3) 0.940
Low 7 (10.3) 32 (47.1)
CD8 Im High 4 (10.1) 22 (31.9) 0.732
Low 8 (11.6) 35 (50.7)
CD8 Tuc High 2 (2.9) 20 (29.4) 0.201
Low 10 (14.7) 36 (52.9)
CD68 Sdc High 4 (6.0) 21 (31.3) 0.753
Low 8 (11.9) 34 (50.7)
CD68 Im High 4 (5.8) 25 (36.2) 0.502
Low 8 (11.6) 32 (46.4)
CD68 Tuc High 2 (2.9) 15 (22.1) 0.463
Low 10 (14.7) 41 (60.3)
Data are presented as n (%). a Only performed in 48 patients. b Some 
histology reports of primary tumors were incomplete. c Some stainings 
(1 – 2 patients) were not analyzable.
 Table 2. Comparison of patient 
characteristics  between those 
receiving and not receiving 
preoperative chemotherapy
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 Other factors like time of occurrence and number of pulmonary metastases that signifi-
cantly influenced survival in a previous study had no implications on survival in our study 
 [22] . This most likely is due to the fact that this huge study with 5,206 patients investigated 
lung metastases of sarcomas, melanomas, germ cells tumors and only to a minor part epithelial 
primary tumors that were not further specified with regard to the number of colorectal carci-
nomas  [22] . This further underlines the importance of our study, which selectively analyzes 
the survival of colorectal carcinoma lung metastases. 
 The retrospective nature, the limited patient number and the lack of a confirmation of the 
results in an independent patient cohort are possible limitations of this study. However, this 
is the first study to compare the immune architecture of colorectal liver and lung metastases. 
 In conclusion, the immune architecture of colorectal liver and lung metastases shows 
differences, with a higher immunological importance of the Tu in lung metastases. More 
specifically, a ‘high’ infiltration of this Tu of pulmonary metastases by CD4 + cells is associated 
with prolonged patient survival. Further, preoperative chemotherapy does not influence the 
local immune infiltrate.
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